Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Garry G Graham

Showing results (1-10 of 50) with videos related to

Pageof 5
Sort By:
Inflammopharmacology|March 24, 2004
Mechanisms of action of paracetamol and related analgesicsGarry G Graham, Kieran F Scott
American Journal of Therapeutics|January 22, 2005
Mechanism of action of paracetamolGarry G Graham, Kieran F Scott
Inflammopharmacology|September 12, 2021
Limitations of drug concentrations used in cell culture studies for understanding clinical responses of NSAIDsGarry G Graham, Kieran F Scott
Drug Safety|March 1, 2005
Tolerability of paracetamolGarry G Graham, Kieran F Scott, Richard O Day
Biochimica Et Biophysica Acta|January 8, 2008
Antibacterial actions of secreted phospholipases A2. ReviewTimo J Nevalainen, Garry G Graham, Kieran F Scott
Drugs|February 5, 2004
[Tolerability of paracetamol]Garry G Graham, Kieran F Scott, Richard O Day
Current Pharmaceutical Design|April 12, 2002
Comparative analgesia, cardiovascular and renal effects of celecoxib, rofecoxib and acetaminophen (paracetamol)Garry G Graham, Robert I Graham, Richard O Day
Expert Opinion on Therapeutic Targets|June 5, 2003
Secreted phospholipase A2 enzymes as therapeutic targetsKieran F Scott, Garry G Graham, Katherine J Bryant
Inflammopharmacology|March 10, 2010
FDA proposals to limit the hepatotoxicity of paracetamol (acetaminophen): are they reasonable?Garry G Graham, Richard O Day, Andis Graudins, et al.
The American Journal of the Medical Sciences|March 18, 2008
Optimizing therapy with allopurinol: factors limiting hypouricemic efficacyYewon Chung, Sophie L Stocker, Garry G Graham, et al.
Pageof 5

Showing results (1-10 of 50) with videos related to

Sort By:
Pageof 5
Inflammopharmacology|March 24, 2004
Mechanisms of action of paracetamol and related analgesicsGarry G Graham, Kieran F Scott
American Journal of Therapeutics|January 22, 2005
Mechanism of action of paracetamolGarry G Graham, Kieran F Scott
Inflammopharmacology|September 12, 2021
Limitations of drug concentrations used in cell culture studies for understanding clinical responses of NSAIDsGarry G Graham, Kieran F Scott
Drug Safety|March 1, 2005
Tolerability of paracetamolGarry G Graham, Kieran F Scott, Richard O Day
Biochimica Et Biophysica Acta|January 8, 2008
Antibacterial actions of secreted phospholipases A2. ReviewTimo J Nevalainen, Garry G Graham, Kieran F Scott
Drugs|February 5, 2004
[Tolerability of paracetamol]Garry G Graham, Kieran F Scott, Richard O Day
Current Pharmaceutical Design|April 12, 2002
Comparative analgesia, cardiovascular and renal effects of celecoxib, rofecoxib and acetaminophen (paracetamol)Garry G Graham, Robert I Graham, Richard O Day
Expert Opinion on Therapeutic Targets|June 5, 2003
Secreted phospholipase A2 enzymes as therapeutic targetsKieran F Scott, Garry G Graham, Katherine J Bryant
Inflammopharmacology|March 10, 2010
FDA proposals to limit the hepatotoxicity of paracetamol (acetaminophen): are they reasonable?Garry G Graham, Richard O Day, Andis Graudins, et al.
The American Journal of the Medical Sciences|March 18, 2008
Optimizing therapy with allopurinol: factors limiting hypouricemic efficacyYewon Chung, Sophie L Stocker, Garry G Graham, et al.
Pageof 5